Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

Advancements in next-generation sequencing technologies, increasing adoption of precision oncology, and rising cancer incidence worldwide are driving the genomics in cancer care market growth.Austin, ...

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a ...

Most pharmaceuticals sold today have their origin in a biochemistry laboratory. Drug discovery has traditionally started with a biochemical pathway implicated in a pathophysiological process. An ...

Long before a liver tumor appears, a high-fat diet can push liver cells into a risky survival mode. That is the central ...

The global metagenomics sequencing market size was US$ 1139.3 million in 2021. The global metagenomics sequencing market is forecast to grow to US$ 3,994.01 million by 2030 by registering a compound ...

Abstract: Conventional microarray-based biosensors can only detect a limited number of organisms, and adding sensor capabilities requires re-engineering of reagents and devices to detect the presence ...

Completion of the Human Genome Project has been rapidly followed by the emergence of high-throughput technologies that combine automation, miniaturization, and many other strategies and tools to ...

The flu is caused by influenza viruses, not bacteria. Influenza can cause symptoms like fever, chills, and body aches. Influenza (referred to as the "flu") is a contagious respiratory disease caused ...